Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 18, 2026

Palantir Stock Has Made Its Early Investors Rich. Can It Do It Again?

View original at nasdaq.com
Palantir Stock Has Made Its Early Investors Rich. Can It Do It Again? Key Points Since Palantir Technologies went public a little over five years ago, its shares have gained an enormous amount of value…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Palantir is expected to report $2.56 per share earnings in 2028

    60% confidence
  • Alphabet and Microsoft are well-positioned to penetrate the decision intelligence market through quantum computing integration

    60% confidence
  • Palantir stock probably cannot repeat its 1,700% performance over the next five years

    60% confidence
  • There is no real barrier to entry into the decision intelligence market, particularly for companies like Microsoft or Alphabet that already have many of the technical resources needed

    60% confidence
  • Palantir's per-share profits of $0.63 in 2024 are projected to triple by 2027, and grow another 40% in 2028

    60% confidence
  • Palantir's top line is expected to top $10 billion in 2027

    60% confidence
  • The Motley Fool Stock Advisor team identified 10 best stocks for investors to buy now, and Palantir Technologies was not one of them

    60% confidence
  • The decision intelligence software market will grow by more than 15% per year through 2035

    60% confidence
  • Stock Advisor's total average return is 1,016% compared to 197% for the S&P 500

    60% confidence
  • Competition will reduce pricing power and put pressure on profit margins that Palantir hasn't faced yet

    60% confidence

Data points we hold from this source

S&P 500 · price to earnings ratio25 ratio
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Palantir Stock Has Made Its Early Investors Rich. Can It Do It Again? — Source | Via News | Via News